Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageWe offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2025, all of the top 20 pharmaceutical companies, measured by 2024 revenue, which we refer to as our top 20 pharma industry cohort, licensed our solutions, accounting for $73.7 million, or 37%, of our software revenue and $80.8 million, or 41%, of our annual contract value, or ACV, in 2025.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $56.9MThe company’s own SEC segment disclosure.
- Drug Discovery$22.9M40%
- Hosted Software$12.1M21%
- Drug Discovery Services$11.7M21%
- Maintenance$6.7M12%
- Professional Services$2.6M5%
- Oncology Neurology And Immunology Product$700.0K1%
- Other (3)$223.0K0%
Schrödinger, Inc. (SDGR) reported revenue of $59M in Q1 2026 (quarter ended March 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $60M. For the full year FY2025, revenue was $256M (+23% year on year) and net income −$103M. Its largest product in 2026-Q1 was Drug Discovery at $23M, 40% of the disclosed total, just ahead of Hosted Software at 21%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.
Health Information Services
Ranks #14 of 14 by Smart Score